Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT06760520 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 40 participants, started 2025-01-20 and due to reach its primary completion in 2027-12-20. Interventions recorded: Ivonescimab (SMT112 or AK112) Injection. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete response rate (CR, pCR plus cCR ). Colorectal eligibility wording from the registry: "* histologically or cytologically confirmed colorectal adenocarcinoma with non-distant metastasis". No results are recorded here; the registry entry is the source.